Navigation Links
New Vision Test Helps Detect Early Signs of Glaucoma
Date:5/4/2019

Diopsys Inc, the world leader in modern visual electrophysiology, announces the release of the Diopsys® ffERG/Photopic Negative Response vision test, a new full field electroretinography (ffERG) protocol designed to detect early signs of glaucoma.

By 2050, it is estimated that 6.3 million Americans will have glaucoma, with black Americans having the highest prevalence rate. This disease can lead to irreversible vision loss and blindness, but with timely treatment, disease progression can be slowed. Since there is no cure for glaucoma, early detection is a key factor in preventing loss of sight.

No single test detects glaucoma, as the disease is diagnosed through a comprehensive eye exam that includes several different tests to help build a clinical picture. Unfortunately, sensitive indicators of early glaucoma are difficult to discern, and results from various tests can be equivocal or unreliable.

The new Diopsys® ffERG/Photopic Negative Response (PhNR) vision test fills a diagnostic need by providing doctors objective information on the function of retinal ganglion cells (RGCs) and their axons. RGCs are the neurons that link the eye to the brain and are the cells primarily damaged by glaucoma. Through evaluating how these cells are functioning, Diopsys® ffERG / PhNR results can provide information on “stressed” cells at a subclinical stage, when they have become dysfunctional but are still alive. Eye care professionals can then begin treatment at this early stage, slowing the progression of the disease, and preserving sight for their patients.

“We are committed to helping the eye care community diagnose glaucoma as early as possible, ” said Alberto González García, MD, Chief Medical Officer at Diopsys. “This new ffERG test provides clinicians with a way to objectively evaluate RGC function efficiently in their practices to make the best clinical decisions for their patients.”

Diopsys also offers another objective test of RGC function called pattern electroretinography (PERG). PERG has been shown to detect RGC dysfunction up to 8 years before changes in RNFL thickness as shown on OCT. Both PERG and ffERG/PhNR tests are clinically suitable to evaluate retinal ganglion cell dysfunction and can help eye care professionals in the decision to initiate treatment. The new Diopsys® ffERG / PhNR test has several testing advantages, including the ability to test in a lit room with no refraction needed.

Diopsys plans to showcase Diopsys® ffERG/Photopic Negative Response at several upcoming eye care conferences. For more information, visit Diopsys.com/PhNR.

About Diopsys: As the world leader in modern visual electrophysiology, Diopsys, Inc. (http://diopsys.com/) has done more than any other company to advance the use of electroretinography (ERG) and visual evoked potential (VEP) in the eye care practice. The company’s unique, patented technology helps eye care professionals detect dysfunction early, track disease progression, and tailor treatment using objective results of visual function.

Read the full story at https://www.prweb.com/releases/new_vision_test_helps_detect_early_signs_of_glaucoma/prweb16285291.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology technology :

1. Edmonton to Host Clinical Trial for Nova Oculus Medical Device that Could Help Improve Vision for AMD Sufferers
2. Signia Introduces New Stylish, High-Tech Hearing Aid in Mediaplanet's Vision and Hearing Campaign
3. USARAD Holdings, Inc. Including Its SecondOpinions.Com® Division, Exhibits at RSNA 2018 Annual Meeting Nov. 25-29 Celebrating 10 year anniversary
4. USARAD Holdings, Inc. Including Its SecondOpinions.Com® Division Makes History By Obtaining Blockchain Based Radiology Interpretations Via Cryptocurrency
5. Nvision Biomedical Technologies Launches Pedicle Screw System at NASS
6. Beckman Foundation Names Dr. James G. Fujimoto of the Massachusetts Institute of Technology as 2017 Beckman-Argyros Vision Research Award Winner
7. Microscan To Demonstrate Advancements in Barcode and Machine Vision Technology at AACC Clinical Lab Expo 2017
8. L3 Healthcare’s Clinical Trials Division Becomes Certified Designer for iMedNet eClinical and Electronic Data Management Software
9. USDM Life Sciences Names Holger Braemer, Vice President of EU and UK Division and Managing Director of USDM Europe GmbH in Germany
10. Former Director of FDA Division of Biostatistics, Gregory Campbell, PhD, joins NDA Partners as Expert Consultant
11. Mann Eye Institute Offers Whats Been Called the "Biggest Advancement in Reading Vision Since the Bifocal"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2019)... N.J. (PRWEB) , ... July ... ... announced a long-term strategic agreement for the development and manufacturing of Zolgensma® ... , Through this collaboration, AveXis, a Novartis company, will have dedicated manufacturing ...
(Date:7/11/2019)... ... July 11, 2019 , ... At the most recent stem cell ... eight military Veterans under the R3 Heroes Program. The Veterans included individuals and families ... Program allow anyone to nominate a military Veteran, teacher or first responder to receive ...
(Date:7/9/2019)... ... July 08, 2019 , ... Balluff has been named ... as the 2019 Innovative Product of the Year which highlights cutting-edge advancements and ... Sensors Expo & Conference 2019, held this week in San Jose, ...
(Date:6/26/2019)... ... 26, 2019 , ... Alice Branton today released research results from preclinical trials ... Gluconate, which can prove to be beneficial for treating Hypomagnesemia. , The preclinical trial ... in crystallite size , Over 142% increase in particle size , ...
Breaking Biology Technology:
(Date:8/1/2019)... ... ... John R. Freeman, CPA, has joined BioLabs as Chief Financial Officer. His ... provides premier co-working spaces for life science startups in the most dynamic biotech hubs. ... growth,” says Fruehauf. “BioLabs has expanded to 10 locations in just a few years, ...
(Date:7/26/2019)... ... July 26, 2019 , ... Worldwide Business with kathy ... CEO Phil Deschamps to discuss their potential new treatment option to manage neurological ... neurotech company in the medical device industry that's focused on neurological wellness. With ...
(Date:7/23/2019)... ... 2019 , ... NanoFUSE is pleased to announce ... for spine and orthopedic use. Bioactive glass is a calcium phosphate coated silica ... in orthopedics for over 30 years and now NanoFUSE Biologics has used advanced ...
Breaking Biology News(10 mins):